Fate Therapeutics, Inc. (FATE)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Fate Therapeutics, Inc. (FATE)
Company Performance

Current Price

as of Oct 18, 2024

$3.23

P/E Ratio

N/A

Market Cap

$367.83M

Description

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Metrics

Overview

  • HQSan Diego, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerFATE
  • Price$3.23+0.31%

Trading Information

  • Market Cap$367.83M
  • Float83.31%
  • Average Daily Volume (1m)1,050,696
  • Average Daily Volume (3m)1,394,140
  • EPS-$1.71

Company

  • Revenue$12.32M
  • Rev Growth (1yr)625.83%
  • Net Income-$38.43M
  • Gross Margin30.29%
  • EBITDA Margin-596.01%
  • EBITDA-$40.36M
  • EV$180.98M
  • EV/Revenue14.69
  • P/EN/A
  • P/S30.80
  • P/B0.93
Documents